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Expression of foreign antigens in the context of poliovirus vectors may provide a plausible approach to vaccine develop-
ment. Poliovirus recombinants were constructed by fusing preS surface or core HBV proteins to the poliovirus polyprotein
as previously described (Andino et al., Science, 265, 1448 –1451, 1994). All recombinant viruses replicated with near wild-
type efficiency in tissue culture cells and stably expressed high levels of the HBV antigens. The kinetics of recombinant
RNA synthesis were indistinguishable from that of wild-type poliovirus. Exogenous proteins were not incorporated into the
poliovirus particles, but HBV core proteins self-assembled into 100S particles composed of free HBV core proteins and
fusions with poliovirus capsid proteins. Mice susceptible to poliovirus infection were inoculated with recombinant virus and
elicited humoral immune responses against the HBV antigens. q 1996 Academic Press, Inc.
A successful vaccine should be safe, effective, and regimen which requires several consecutive administra-
tions of the vaccine (Krugman, 1988). Indeed, the Unitedprevent or limit initial replication of a pathogen. In addi-
tion, the vaccine should be easy to store and transport as Nations’ Children’s Vaccine Initiative has identified the
HBV vaccine as one existing vaccine that needs to bewell as capable of being administered in a cost effective
manner. The latter attribute has the greatest impact for improved (La Montagne and Rabinovich, 1992).
Given the favorable characteristics of the Sabin polio-vaccination programs in the developing world, where
most of the epidemic viral diseases occur and where virus vaccine, a number of investigators have attempted
to adapt poliovirus as a vector to express antigens fromvaccines could have the greatest impact on public health.
The Sabin live attenuated poliovirus vaccine is easily other pathogens. The poliovirus genome consists of a
single strand, positive sense RNA molecule of approxi-administered by the oral route, has a low distribution
cost, induces both serum antibodies and intestinal muco- mately 7500 nucleotides. A unique open-reading frame
encodes a large polyprotein precursor, which must besal resistance, confers long lasting immunity, and has
greatly facilitated the control of widespread paralytic po- proteolytically processed by two viral proteinases (2Apro
and 3Cpro) in order to generate mature structural andliomyelitis epidemic (Dowdle et al., 1994).
In contrast, despite the existence of an effective vac- nonstructural poliovirus proteins. The major viral prote-
ase, 3Cpro, recognizes and cleaves at specific amino acidcine, HBV continues to be a major cause of acute and
chronic hepatitis, cirrhosis, and hepatocellular carci- sequences (AXXQG) within exposed polyprotein do-
mains.noma (Hollinger, 1990). Worldwide, there are now more
than 250 million people infected with HBV. The majority Several strategies have been reported in the engi-
neering of poliovirus vectors. Through one method, smallof these individuals live in developing countries. In South-
east Asia, China, and sub-Saharan Africa, the prevalence antigenic epitopes are inserted into one of the capsid
proteins, VP1 (Burke et al., 1988; Evans et al., 1989).of HBV infection is as high as 5–15% of the total popula-
tion. In the United States, where the prevalence rate of Through another method, dicistronic poliovirus RNAs are
constructed by duplicating the 5* noncoding region ofchronic hepatitis is among the lowest in the world (0.1 –
1%), approximately 200,000 cases of new HBV infections the poliovirus genomic RNA (IRES). In this manner, the
foreign polypeptide is expressed using one IRES andoccur each year (Hollinger, 1990; Krugman, 1988).
The lack of success in controlling global HBV infection essential viral proteins are produced using the other (Al-
exander et al., 1994; Lu et al., 1995). A third method usesin highly endemic areas is due in large part to the lack
of an inexpensive vaccine and the complex vaccination poliovirus minireplicon genomes in which poliovirus
structural protein genes are replaced by foreign se-
quences (i.e., HIV-1 gag, env, and pol), in this case mini-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (415) 476-0939; e-mail: andino@cgl.ucsf.edu. replicon genome must be packaged by supplying poliovi-
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rus capsid proteins in trans (Choi et al., 1991; Porter Poliovirus chimeras were constructed by individually
cloning three specific antigenic HBV proteins into a mo-et al., 1995; Ansardi et al., 1995). Limitations of these
strategies include the small size of the tolerated insert, lecular clone of Mahoney Type 1 wild-type poliovirus
vaccine vector (pMoV-1.4) (Andino et al., 1994). The Ma-genetic instability of the inserted sequences, or a re-
quirement for helper virus for viral propagation. honey vector cDNA has been modified to include an in-
frame synthetic polylinker containing EcoRI, NotI, BssHII,We have pursued a different approach that utilizes
basic aspects of the viral life cycle and permits the gener- and XhoI sites that facilitate the insertion of foreign se-
quences; an artificial recognition and cleavage siteation of replication-competent recombinant polioviruses
that are able to replicate without the need for a helper (AXXQG) for the major poliovirus protease (3Cpro) was
placed at the 3* border of the polylinker and was pre-virus and that stably carry and express genetic se-
quences of other pathogens (Andino et al., 1994). Se- ceded by a six polyglycine tract.
quences are inserted at the amino terminus of the polio- Exogenous DNA sequences were amplified by PCR
virus polyprotein precursor, separated by an artificial 3C (Ausubel et al., 1994) with primers that included restric-
protease cleavage site. In this way, a larger than normal tion enzyme recognition sites to facilitate the insertion
precursor is initially made, but is appropriately cleaved of the PCR amplified exogenous DNA into the vector
into the usual array of constituent proteins. The 3C prote- polylinker. Coding sequences for the preS1 region of
ase accurately recognizes and cleaves the inserted syn- HBV was amplified with primers 1 and 2; the preS2 region
thetic proteolytic site, freeing the exogenous protein se- of HBV was amplified with primers 3 and 4; and a HBV
quences from the rest of the poliovirus polyprotein (Fig. core region was amplified with primers 5 and 6. All three
1A). In this manner, all of the poliovirus proteins are sequences were amplified using plasmid containing
correctly produced and normal viral replication proceeds. HBVadw2 sequences as a template (a gift from the Don
This method has been used to express antigenic deter- Ganem laboratory). PCR fragments used in cloning were
minants derived from a large number of bacterial and digested with BssHII and NotI restriction enzymes and
viral pathogens (Andino et al., 1994; Mattion et al., 1994; ligated to the vector digested with the same enzymes
Altmeyer et al., 1994). Importantly, Altmeyer and co-work- (Ausubel et al., 1994). Restriction sites (SalI and XhoI)
ers have employed a different picornavirus, Mengovirus, were introduced at codon 79 of the HBV core insert using
to express a cytotoxic T-cell epitope from lymphocytic overlap PCR extension technique with primers 16 and
chorio-meningitis virus (LCMV). The mengovirus recom- 14 and 15 and 17. This recombinant, named HBc.SX,
binant can elicit immune responses that protect vacci- was used to construct polioviruses carrying HBV core
nated mice against challenge with pathogenic strain of chimeric particles which display on their surface HBV
LCMV (Altmeyer et al., 1995). preS1 and preS2 antigenic peptides. Antigenic peptides
As a first step toward the development of a alternative, coding sequences were PCR amplified and ligated to
cheaper, and more effective HBV vaccine we have de- HBc.SX plasmid. HBV preS1 sequences were amplified
scribed in this report the construction and characteriza- using primers 18 and 19, and HBV preS2 was constructed
tion of poliovirus recombinants carrying surface and core by inserting the double-strand oligonucleotide (20 and
HBV antigenic sequences. Foreign HBV amino acid se- 21). Replication-competent chimeric polioviruses were
quences were produced in significant amounts in poliovi- recovered by transfection of HeLa S3 cells with in vitro
rus chimera-infected cells, but the foreign peptides were transcribed RNA from recombinant cDNA clones (Luth-
not included in the poliovirus particle. Infection of sus- man and Magnusson, 1983).
ceptible mice with the poliovirus recombinants elicited
humoral immune responses to both HBV and poliovirus
Cells and virus stocksproteins.
HeLa cells, clone S3, were grown in suspension inMATERIALS AND METHODS
Jokliks modified minimal essential medium (MEM; Sigma
Poliovirus recombinant construction and DNA Chemical Company, St. Louis, MO) supplemented with
procedures 10% horse serum (GIBCO Diagnostics, Madison, WI), 1%
penicillin–streptomycin, and 1% L-glutamine (both fromRestriction enzymes, T4 DNA polymerase, Taq poly-
Mediatech, Inc., Herndon, VA).merase, T7 RNA polymerase, and avian myeloblastosis
HeLa cell monolayers in 100-mm dishes were grownvirus reverse transcriptase (AMV RTase) were obtained
in DMEM/F12 (GIBCO) and transfected with 1–10 mg offrom Boehringer Mannheim Biochemicals (Indianapolis,
recombinant viral RNA by a DEAE–dextran procedureIN); T4 DNA ligase was obtained from New England Bio-
(Luthman and Magnusson, 1983). Single plaques wereLabs, Inc. (Beverly, MA); and shrimp alkaline phospha-
isolated and expanded for each poliovirus chimera bytase came from the United States Biochemical Corp.
standard procedures to generate stocks that were used(Cleveland, OH). All enzymes and compounds were used
as recommended by the manufacturers. for further characterization.
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Virus infections mM MgCl2 , 1 mM DTT, 1% Triton X-100, and 0.1 mM
phenylmethylsulfonyl fluoride (PMSF)] and the nuclei
In all experiments, 100-mm dishes containing approxi- were removed by centrifugation (Andino et al., 1993). Four
mately 31 106 cells were used. The dishes were washed micrograms of proteins of total lysates was subjected to
once with phosphate-buffered saline (PBS) and the ap- electrophoresis through a 12% SDS–polyacrylamide gel
propriate amounts of virus were added in order to yield and analyzed by immunoblotting. Antisera against the
the desired multiplicity of infection (m.o.i.). Plates were poliovirus capsid proteins was prepared in a rabbit. A
incubated at room temperature for 30 min, allowing the monoclonal antibody that reacts with HBV preS1 region
virus to bind to the cells, and then 10 ml of Dulbecco’s was a gift from the Mena Ostapchuck’s laboratory (Suny –
Modified Eagle Medium [Nutrient Mixture F-12 (DMEM/ Stony Brook), antisera to the HBV preS2 region was a gift
F12) 1:1 Mixture (Mediatech)] supplemented with 10% from Patricia Reilly (American Cyanamid), and antisera
newborn calf serum (GIBCO), 1% penicillin–streptomy- to the HBc was obtained from DAKO (Carpinteria, CA).
cin, and 1% L-glutamine (Mediatech) was added to the Antisera directed against poliovirus capsid proteins were
dishes and placed at appropriate temperature, as re- obtained by inoculating rabbits with purified poliovirus.
quired for each specific experiment. At the time of collec- Secondary antibodies (both anti-mouse and anti-rabbit)
tion, plates were washed once with PBS, and cells were were obtained from Amersham (Arlington Heights, IL).
resuspended in 1 ml of PBS. Cells were collected by The immunoblotting procedure was provided by the man-
centrifugation at low speed and stored at0207 until anal- ufacturer of the ECL chemiluminescense detection kit
ysis. (Amersham).
One-step growth curve Measurement of viral RNA synthesis
HeLa cells were infected as previously described withHeLa cell monolayers in 100-mm dishes were infected
an m.o.i. of 10 for each of the recombinant and wild-typewith each recombinant, as described above, with an
polioviruses. After 30 min of adsorption of the virus atm.o.i. of 10 and incubated at different temperatures. At
377, the cells were washed with PBS, and DMEM/F12each time point, infected cells were collected and lysed
containing Actinomycin D (5 mg/ml) was added. [3H]-by freeze-thaw. Viral yield (plaque-forming units per milli-
Uridine (20 mCi/ml) (purchased from Du Pont NEN Re-liter[pfu/ml]) at each time point was determined by
search Products, Boston, MA) was added at 1 hr postin-plaque assay (Trono et al., 1988).
fection. Cells were collected as previously described at
RT–PCR various time points. Acid insoluble materials were col-
lected onto Millipore glass microfiber filters, and radioac-
Each passage on tissue culture was performed by in-
tivity was determined by scintillation counting (Bernstein
fecting HeLa cells with a m.o.i. of 10, and incubating the
et al., 1985).
infected cells at 377 for 24 hr. Total RNA from cells in-
fected with a recombinant virus was prepared by phe- Cesium chloride gradient analysis
nol–chloroform extraction 9 hr postinfection and precipi-
Viruses were metabolically labeled by infecting Hela
tated with ethanol. Reverse transcription (RT) was per-
cells with wild-type or recombinant poliovirus for 8 hr at
formed with AMV RTase at 427 for 60 min using oligo 13
377 in the presence of 25 mCi/ml of 35[S]methionine. Cells
as a primer, complementary to the viral RNA sequences
were lysated in buffer H and cytoplasmic extracts were
located approximately 60 bases downstream from the
clarified by centrifugation and loaded in a CsCl solution
inserted sequences. After the reaction was completed,
(1.4 g/ml). Gradients were submitted to centrifugation for
the enzyme was inactivated by incubating it at 1007 for 3
20 hr at 35000 rpm; then they were fractionated in ali-
min. Polymerase chain reaction (PCR) amplification was
quots of 0.5 ml, the radioactivity in each aliquot deter-
performed with primers 7 and 8 to amplify the region of
mined by scintillation counting.
the poliovirus genome that contained the inserted se-
quences. Note that these primers amplify both wild-type Sucrose gradient analysis
and recombinant sequences, and the method is semi-
Lysates from HeLa cells infected with a recombinant,
quantitative. PCR was performed for 25 cycles at 947
HBc.155, or a wild-type virus were analyzed by sucrose
for 1 min, 507 for 1 min, and 727 for 1 min using Taq
gradient (10–60%) as described by Zhou and Standring
polymerase.
(1991). Fourteen fractions (100 ml each) were collected
and HBV or poliovirus-specific proteins were detectedWestern blot analysis
by immunoblotting as previously described.
HeLa cells infected with wild-type and HBV recombi-
Expression of HBV proteins in E. colinant polioviruses (m.o.i. of 10) were incubated for 4, 6,
and 8 hr at 377. Cells were harvested and lysed in buffer The pGEX expression system (Smith and Johnson,
1988) was used to produce HBV proteins used in ELISAH [buffer H: 10 mM Hepes (pH 7.9), 10 mM KCl, 1.5
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determinations. Plasmids were constructed using the
pGEX -4T-1 glutathione S-transferase (GST) Gene Fu-
sion Vector System (Pharmacia Biotech, Inc., Piscata-
way, NJ). Inserts were amplified by PCR using primers
9 and 10 for pGEX-4T-1-S2B and primers 11 and 12
for pGEX-4T-1-HBc. PCR fragments were digested with
BamHI and NotI restriction enzymes and ligated to the
pGEX -4T-1 which was also digested with the same
enzymes. The proteins were expressed and purified
according to the protocol recommended by the manu-
facturer (Pharmacia).
Inoculation of transgenic mice with recombinant
poliovirus and determination of antibody titers by
enzyme-linked immunosorbent assay (ELISA)
Mice (TgPVR1-17 strain) (Ren et al., 1990), generously
provided by American Cyanamid, were infected intraperi-
toneally with 100 ml of 1 1 108 PFU/ml stocks of either
wild-type or recombinant polioviruses (HBV.S2 or HBc-
155). Also as a negative control, mice were mock infected
by intraperitoneal injection of 100 ml PBS. Mice were
inoculated at 0, 2, 5, and 8 weeks. Sera obtained from
infected mice at 0, 2, 5, 8, and 11 weeks after the first
inoculation were analyzed by ELISA. ELISA procedure
was basically conducted as described (Ausubel et al., FIG. 1. (A) Schematic diagram of a recombinant poliovirus vector
and strategy for expression of HBV proteins. The bar represents recom-1994). Plates coated with 5 mg/ml of purified GST preS2
binant poliovirus genomic RNA. Viral genes are indicated within corre-fusion protein or GST– HBV core fusion protein (ex-
sponding boxes, and the exogenous sequence at the 5*-end of thepressed in pGEX) were incubated with doubling dilution
open-reading frame is indicated by a striped box. Sequences sur-
of test samples. Bound antibody was detected by incuba- rounding the insertion point of the exogenous sequence are detailed:
tion with antibodies to mouse Ig antibodies conjugated to the start codon, additional amino acids flanking the exogenous se-
quence providing a restriction enzyme polylinker, a poly-glycine tract,horseradish peroxidase (Amersham). Enzymatic activity
the 3Cpro artificial cleavage site, and the amino terminus of the viralwas determined with ABTS tablets (Boehringer). The ab-
polyprotein. Following translation of the viral RNA, a larger than wild-sorbance was measured at 405 nm. Results are ex-
type polyprotein is produced, but proteolytic processing of the natural
pressed as the reciprocal of the lowest dilution that gave and artificial cleavage sites (indicated by triangles) results in the re-
an absorbance of 0.1–0.15 units above the background. lease of the foreign peptide and the generation of mature and functional
viral proteins. (B) Denomination of each HBV-recombinant poliovirusBackground controls included assay plates coated with
constructed. The inserted HBV proteins and their lengths (in nucleo-5 mg/ml of GST as well as evaluation of preimmune sam-
tides and amino acids) are indicated.ples. The reproducibility of the ELISA after three repeated
assays of the same sample of serum was within one
dilution. 20: GAG CTC CCC AGA GTC AGG GGT CTG TAT CTT CCT GCT GGT CTC GAG
21: CTC GAG ACC AGC AGG AAG ATA CAG ACC CCT GAC TCT GGG GAG CTC
Oligonucleotides
RESULTS1: GAA TTC GGA GCG GCC GCT GGA GGT TGG TCA TCA AAA
2: TGA CTC GAG GCG CGC GGC CTG AGG ATG ACT GTC
3: GAA TTC GGA GCG GCC GCT CAG TGG AAT TCC ACT GCC Replicative characteristics of HBV-recombinant
4: TGA CTC GAG GCG CGC GTT CGT CAC AGG GTC CCC poliovirus5: GGC TGC TCA GGA ATT CCT TGG GTG GCT TTG GGG C
6: CAA CCC CGA GGC GCG CAA CAA CAG TAG TTT CCG G
7: AGT TAT TTC AAT CAG ACA AT The poliovirus vector (pMoV-1.4) was constructed
8: TGA GTT TTC ATG TGC GCC CAC from biologically active cDNA clones of wild-type Ma-9: TTC CCG GGT CGA CTC CAG TGG AAT TCC ACT
10: GTC ACG ATG CGG CCG CTC GTT CGT CAC AGG GTC honey type 1 strain, as recently described (Andino et
11: GTT CCG CGT GGA TCC CTT GGG TGG CTT TGG al., 1994). Mahoney rather than Sabin type 1 was cho-12: GTC ACG ATG CGG CCG CTC AAC AAC AGT AGT TTC
13: GCC CAC TTT CTG TGA sen because the available strain of susceptible mice
14: GCT GCT CAG GAA TTC CTT GGG TGG CTT TGG G does not well support Sabin type 1 replication (Andino,
15: CCA ACC CCG AGG CGC GCA ACA ACA GTA GTT TCC GG
16: AGC CTC GCC TCC ACC TCC GCC AAC CCC GAG GCG CGC AAC AAC AGT AGT TTC 1994). Five chimeric polioviruses were prepared by in-
17: CGG AGG TGG AGG CGA GGC TTT GTT TCA AGG TGC TCA GGT TTC ATC serting nucleotide sequences encoding for HBV anti-
18: TAC CTG GGT GGA GCT CCA TCA GTT GGA CCC T
19: ACG ACT GGC CAG CAC TCG AGA ATA ATT T gens into MoV-1.4 (Fig. 1B). The antigens include the
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amino-termini of preS1 and preS2 HBV presurface anti- Expression of the foreign proteins by poliovirus
chimerasgens (118 and 54 amino acids, respectively); 155 amino
acids from the amino terminus of the HBV core protein;
To determine whether recombinant viruses expressedand HBV core hybrids that display immunogenic epi-
the foreign polypeptides, HeLa cells were infected withtopes derived from preS1 (amino acids 27 to 53: HQLD-
wild-type and chimeric polioviruses, and cytoplasmic ex-PAFGANSNNPDWDFNPVKDDWPA) and preS2 (amino
tracts were obtained at different times following infectionacids 133 to 143: PRVRGLYLPAG) on their surface (in-
and analyzed by immunoblotting. Poliovirus capsid pro-serted between amino acid 79 and 80). It has been
teins were produced and correctly processed in recombi-shown that peptide immunogenicity can be greatly en-
nants HBV.S1 and HBV.S2; however, poliovirus proteinshanced by presentation on the surface of HBV core
accumulated at lower levels in recombinant infected
particles (Schodel et al., 1993); thus, antigenic portions
cells than in wild-type infected cells (Fig. 3A, lanes 1–10).
of the HBV preS proteins were inserted in a region of
All recombinants also expressed the expected foreign
the core sequence shown to be expressed on the sur-
proteins in the infected cells as detected by antibodies
face of the core particle (Crowther et al., 1994).
directed against the foreign proteins (Fig 3A, lanes 13,
All chimeric poliovirus-cDNAs yielded replication- 14, 17, and 18; Fig. 3B, lanes 6–17). In cells infected with
competent viruses after transfection of HeLa cells with recombinant HBV.S1, anti-preS1 antibodies detected a
in vitro synthesized RNA. At 327 and at 377, recombi- single polypeptide (Fig. 3A, lanes 13 and 14). The molecu-
nants HBV.S1, HBV.S2, and HBc.155 produced plaques lar weight of this polypeptide suggests that the detected
similar in size to wild-type plaques. However, at 397, band corresponds to the preS1 free polypeptide. Recom-
recombinants produced plaques that were smaller binant HBV.S2 produced two distinct bands that were
than those corresponding to wild-type virus (Fig. 2A). recognized by anti-preS2 antibodies (Fig. 3A, lanes 17
A one-step growth curve of poliovirus wild-type and and 18). Based on molecular weight (see Fig. 3 legend),
recombinants confirmed the temperature-sensitive na- the larger band probably corresponds to a fusion be-
ture of the chimeric poliovirus (Fig. 2B). At 397 and at tween preS2 and Vp0 / Vp3, and the smaller band to
377, both wild-type and recombinants achieved maxi- the free preS2 protein. Extracts from cells infected with
mal titers at 6 hr postinfection. However, recombinant recombinants HBc.pS1 and HBc.pS2 displayed only a
viruses replicated more slowly than the parental wild- single immunoreactive polypeptide band of expected mo-
type, and yielded approximately 1% of wild-type titers. lecular weight corresponding to the HBV core protein
At 327, both wild-type and recombinants exhibit de- fused to the antigenic peptide derived from preS1 and
layed replication, but by 12 hr postinfection, chimeric preS2 proteins (Fig. 3B, lanes 10–13 and 14–17, respec-
viruses achieved 50 – 70% of wild-type titers. Replica- tively). Extracts from cells infected with poliovirus recom-
tion of recombinants HBc.pS1 and HBc.pS2 in HeLa binant HBc.155 showed three polypeptides that reacted
cells was indistinguishable from HBc.155 (data not with anti-HBV core antibodies. Based on molecular
shown). weight, these bands probably correspond to fusions be-
tween the HBV core and capsid precursors Vp0 or Vp0-To determine the genetic stability of recombinant po-
Vp3 and the free HBV core protein (Fig. 3B, lanes 6–9).lioviruses, the regions of the genome containing the in-
serted sequences were amplified by RT–PCR (Fig. 2C).
RNA synthesis of poliovirus recombinantsPrimers were chosen to amplify either wild-type or re-
combinant sequences around the site of insertion. Be-
Replication characteristics of poliovirus recombinantscause the PCR assay is semiquantitative, the ratio be-
were further analyzed by measuring their ability to syn-tween bands corresponding to wild-type and recombi-
thesize viral RNA. HeLa cells were infected with wild-
nant sequences should represent ratio between
type or recombinant viruses, and infected cells were in-
recombinant and revertants present in a given viral stock.
cubated at 377 in the presence of [3H]uridine and Actino-
The genetic structure of recombinant HBV.S2, HBc.155,
mycin D to inhibit cellular RNA synthesis. Incorporation
HBc.pS1, and HBc.pS2 were stable after six rounds of
of [3H]uridine into viral RNA was determined by acid pre-
replication in HeLa cells. Recombinant HBV.S1 appears cipitation at several time points. Rates of synthesis for
to be less stable; the inserted sequences were fully re- all recombinant polioviruses were very similar to that of
tained for only four rounds of replication, and smaller the wild-type virus (Fig. 4A), suggesting that reduction in
bands corresponding to wild-type sequences emerged replication indicated by the one-step growth curve does
after the fifth and sixth passages. However, even in this not result from impaired RNA synthesis (see Discussion).
recombinant, a substantial proportion of the virus popula-
tion still retained the foreign insert after the sixth pas- Cesium chloride gradient analysis
sage. Based on these results, all further experiments
presented in this report were performed using viral The physical properties of the recombinant polioviri-
ons were examined using cesium chloride (CsCl) gra-stocks obtained after three passages in HeLa cells.
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FIG. 2. Growth characteristics of poliovirus recombinants. (A) Plaque assays of wild-type and recombinant HBV.S1 (carrying 118 amino acids of
HBV preS1), HBV.S2 (54 amino acids of HBV preS2), and HBc.155 (155 amino acids of HBV core) were performed in HeLa cells at different
temperatures (327, 377, and 397) for 48 hr. (B) One-step growth curves for three recombinant polioviruses. HeLa cell monolayers were infected (m.o.i.
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FIG. 3. Expression and processing of the exogenous proteins in cells infected with recombinant polioviruses. Cytoplasmic lysates from HeLa
cells infected with wild-type poliovirus or various recombinant viruses were analyzed by Western blot with antibodies directed against poliovirus
virions [a-capsid, (A) lanes 1– 10], preS1[a-S1, (A) lanes 11–14], preS2 [a-S2, (A) lanes 15–18], HBV core [a-HBV-core, (B) lanes 1–17]. Mock:
mock-infected HeLa cells; wild-type: poliovirus wild-type; HBV.S1: HBV preS1-recombinant; HBV.S2: HBV preS2-recombinant; HBc.155: HBV core-
recombinant; HBV.pS1: HBV core fused to preS1 peptide-recombinant; and HBV.pS2: HBV core fused to preS2 peptide-recombinant. Poliovirus
capsid proteins are indicated by shaded triangles. Molecular weight markers indicate relative mobility. Bands detected by specific antibodies
directed against the inserted sequences are indicated by dots: (S1) free preS1 (16.5 kDa); (S2) preS2-Vp0 / Vp3 fusion (64 kDa); (S2*) free preS2
(9.7 kDa); (core) free HBV core (19.5 kDa), (core.S1) HBV core containing preS1 26 amino acid peptide (23 kDa), and (core.S2) HBV core containing
preS2 11 amino acid peptide (21 kDa). Background bands recognized by anti-S2 antibodies are represented by a ‘‘b.’’
dients. Viruses were metabolically labeled by infecting tectable foreign proteins (data not shown), suggesting
that exogenous proteins are excluded from the matureHeLa cells with wild-type or recombinant polioviruses
in the presence of [35S]methionine. Eight hours postin- recombinant virus particle.
fection, viruses were extracted from infected cells in
buffer H, then loaded onto a 1.4 g/ml CsCl solution. HBV core particle formation
Following centrifugation, radioactivity present in each
fraction was determined by scintillation counting (Fig The HBV core particle is a strong immunological adju-
vant. Since peptides fused to the HBV core protein elicit4B). The buoyant densities determined for wild-type
and recombinant viruses were almost identical (1.35 longer-lasting and much stronger antibody responses
against the inserted peptides than do the free peptides,g/ml), suggesting that the recombinant particle is very
similar to the wild-type particle. It is interesting that it has been proposed that HBcAg may act as an efficient
T-cell carrier moiety (Schodel et al., 1993; Milich et al.,samples from HBV.S2- and HBc.155-infected cells
showed more radiolabeled material at the top of the 1987). In fact, the HBV core antigen has been shown to
efficiently elicit responses from both T cells and B cellsgradient, perhaps reflecting instability of the recombi-
nant virus particles under the gradient conditions. It is (in a T-cell-independent manner). This enhanced immu-
nogenicity appears to depend in part on the ability ofsomewhat surprising that the larger size of the genome
of recombinant viruses (102 to 106% of the wild-type HBV core hybrids to assemble into particles that display
on their surface the inserted antigenic peptide (Schodelsize) did not result in a higher density particle; perhaps
the difference in density (1.38 g/ml vs 1.35 g/ml) is too et al., 1993; Clarke et al., 1988; Milich et al., 1987).
To determine whether HBV core, expressed by thesmall to be detected under our experimental condi-
tions, or the volume of the recombinant viral particle is poliovirus recombinants, indeed assembled into parti-
cles, HeLa cells were infected with the recombinantchanged by the larger genome of recombinant viruses.
Because the HBV peptides are expressed as fusions to HBc.155 for 7 hr, after which cytoplasmic extracts were
analyzed by sucrose gradient sedimentation followed bythe poliovirus capsid proteins, we asked whether some
foreign antigens may remain fused and become incorpo- immunoblotting. Fractions 8 to 12 (100s) contained
polypeptides that were detected with anti-HBV core anti-rated into recombinant particles. CsCl-purifed recombi-
nant viruses were analyzed by Western blot using anti- bodies (Fig. 5). The molecular weights of these polypep-
tides suggest that HBV particles formed after poliovirusbodies against the foreign proteins. None contained de-
 10) with wild-type poliovirus, recombinant HBV.S1, HBV.S2, and HBc.155. Virus production (PFU/ml) was determined at each time point. (C)
Analysis of the stability of recombinant poliovirus genomes. HeLa cells were infected with recombinant viruses obtained after 2, 3, 4, 5, or 6
successive passages in HeLa cells. The presence of the foreign sequence insertion was analyzed by RT-PCR, using total cytoplasmic RNA of
infected cells as a template for reverse transcription.
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FIG. 4. (A) Viral RNA synthesis of wild-type and recombinant polioviruses. HeLa cells were infected with an m.o.i.  10 and incubated at 377 in
DMEM containing 5 mg/ml of actinomycin D and 20 mCi/ml of [3H]uridine. Cytoplasmic extracts were obtained at each time and [3H]uridine
incorporated to an acid-insoluble fraction was measured by scintillation counting. (B) Cesium chloride gradient of wild-type and recombinant
polioviruses. Metabolically labeled viruses were submitted to centrifugation in CsCl gradient. Aliquots of 0.5 ml were collected and radioactivity
determined. The buoyant density determined by weighing each fraction was 1.35 g/ml for both wild-type and recombinant particles.
infection consist of free HBV core protein and fusions of poliovirus receptor and are susceptible to poliovirus in-
fection (Ren et al., 1990). Mice were inoculated intraperi-the HBV core protein with poliovirus Vp0 or Vp0–Vp3. In
addition, antibodies directed against poliovirus capsid toneally on four occasions (0, 2, 5, and 8 weeks), either
with HBV.S2 or HBV.155, or controls (wild-type poliovirusproteins immunoprecipitated HBV free core polypeptide
from HBc.155 infected-cell extracts, suggesting that the or saline). Serum samples were obtained at the day of
the first inoculation and at 2, 5, 8, and 11 weeks after.HBV core particle is constituted by free and fused HBV
core protein. It is remarkable that the HBV particle could The induction of specific antibodies directed against HBV
proteins was analyzed by ELISA. Serum antibodies rec-still be formed by the HBV core protein fused to a large
portion of poliovirus capsid proteins. ognizing HBV preS2 and core polypeptides were readily
detected in all poliovirus recombinant-infected animals
within 2 weeks of the first inoculation (Fig. 6). Interest-Immune responses to the HBV sequences
ingly, antibody response elicited against the HBV pro-
The immunogenicity of the recombinant poliovirus was teins achieved similar titers to those obtained against
examined in transgenic mice that express the human poliovirus capsid proteins (103 reciprocal dilution; data
not shown). In addition, wild-type and recombinant polio-
virus elicited similar antibody response against poliovi-
rus capsid proteins. Finally, though all recombinants
used are based on wild-type type 1 Mahoney strain none
of the mice were paralyzed, suggesting that the insertion
of foreign sequences at the polyprotein amino terminus
somehow attenuates poliovirus virulance.
DISCUSSION
In this study, we have shown that replication-compe-
tent poliovirus can be generated when HBV antigens are
fused to the poliovirus polyprotein. In general, recombi-
nants replicated more slowly than the wild-type virus,
and the difference was greater at 397 than at 327. PerhapsFIG. 5. HBV core particles produced in recombinant poliovirus-in-
faster replication rates at higher temperatures accentu-fected cells. Extracts from HeLa cells infected with the HBc.155-recom-
binant poliovirus (carrying 155 amino acids of HBV core) were submit- ate slight defects in one or more replicative steps.
ted to sucrose density gradient analysis (10 to 60%). Aliquots from each Because RNA viruses in general lack efficient proof-
fraction were analyzed by 10% SDS–PAGE and by immunoblots using reading mechanisms, one concern about using poliovirus
antibodies directed against HBV core. Molecular weight markers indi-
as a vaccine vector is that inserted sequences may becate relative mobility. Bands corresponding to the HBV core (19.5 kDa),
genetically unstable. We found that the recombinantsHBV core-Vp0-Vp3 (83 kDa), and HBV core-Vp0 (57 kDa) fusions are
indicated by shaded arrows. described here stably carry foreign sequences for at
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wild-type and recombinant polioviruses and found no del-
eterious effect of the insert. Because most poliovirus
polypeptides, except the structural proteins, participate
in RNA synthesis, the growth defect observed for poliovi-
rus recombinants is more likely to relate to capsid forma-
tion, RNA packaging, or particle release.
Expression of the HBV core protein by HBc.155 results
in production of HBV hybrid particles composed of free
HBV core protein and fusions of HBV core to Vp0 or Vp0–
Vp3. It appears that the poliovirus protease inefficiently
cleaves at the artificial site once the HBV hybrid particle
has been formed, since fusions of HBV core and poliovi-
rus capsid proteins are readily detected in fractions con-
taining HBV particle (Fig. 5, lanes 9–13). In contrast, frac-
tions corresponding to free nonparticulate proteins (Fig.
5, lanes 1–5) contained no detectable fusion proteins.
All mice inoculated with poliovirus recombinants
(HBV.S2 and HBc.155) developed an antibody response
against the HBV proteins, whereas control mice (inocu-
lated with nonrecombinant poliovirus or saline) showed
no immunoreactivity (Fig. 6). Antibody titers elicited
against preS2 and HBV core were similar to those pro-
duced against poliovirus capsid proteins (data not
shown). Because the poliovirus capsid proteins are very
immunogenic, it appears that preS2 and core expressed
by poliovirus vectors are also highly immunogenic. How-
ever, it will be important to compare antibody titers ob-
tained after exposure to recombinant poliovirus with
those obtained by direct inoculation of HBV proteins as
used in the current vaccine formulation. We did not at-
tempt to address this question in the transgenic mouse
FIG. 6. Immunization of poliovirus receptor (PVR)-transgenic mice model because it would be difficult to extrapolate any
with the HBV.S2- or HBC.155-recombinant poliovirus elicited a humoral result to the human situation. A more relevant system
response against the HBV inserted proteins. Six PVR-transgenic mice (such as chimpanzees or humans) would be necessary(Nos. 402, 428, 429, 412, 226, and 231) were infected with the HBV
to further investigate the potential of poliovirus recombi-preS2-recombinant virus (HBV.S2), and six mice (Nos. 406, 407, 398,
nants as a human HBV vaccine.399, 408, 409) with HBV core-recombinant poliovirus (HBc.155). As a
control mice were inoculated with either poliovirus wild-type (WT) or In addition to the beneficial attributes of Sabin live
saline (PBS). Animals were infected by intraperitoneal injection with attenuated vaccine, HBV-recombinant polioviruses
100 ml of 1 1 108 PFU/ml of viral stock; they received four identical would be expected to simultaneously elicit immunityinoculations separated by a period of 2 or 3 weeks. At 0, 2, 5, 8, and
against both poliovirus and HBV; indeed, is possible to11 weeks after the first inoculation serum samples were obtained and
imagine a broad range vaccination against multipleanalyzed by ELISA, using multiwell plates coated with preS2 (A) or
HBV core (B) GST-fusion proteins. Antibodies reacting with the HBV pathogens by using a ‘‘cocktail’’ of recombinant poliovi-
proteins were visualized with anti-mouse total Ig-specific second-stage ruses, each expressing a different antigen.
antibodies conjugated to horseradish peroxidase.
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